NEW YORK (AP) — Drugmaker Bristol-Myers Squibb Co. made a raft of leadership changes Tuesday, creating a senior council of four executives, promoting its chief operating officer to president, and broadening the responsibilities of four other executives. Lamberto Andreotti, 58, was named to the new post of president in addition to his responsibilities as COO. He was also elected to the board of directors. Bristol-Myers said Andreotti will be part of its Executive Committee, which will make strategic choices for the company. The other members of the committee are Chairman and Chief Executive Jim Cornelius, 65; Chief Financial Officer Jean-Marc Huet, 39; and Chief Scientific Officer and President of Research & Development Elliot Sigal, 57. "This group will chart the future for Bristol-Myers Squibb," Cornelius said in a press release. The New York-based company is working on a strategy called "String of Pearls," with the goal of becoming a biopharmaceutical company by acquiring biotech drugs and selling noncore businesses. The "pearls" are 10 major diseases the company is prioritizing. Bristol-Myers also said Anthony Hooper will take an expanded role as president of its Americas business. Hooper, 54, had been president of the U.S. pharmaceuticals division. Beatrice Cazala, 53, is now president of global commercialization and president of the European business. Cazala previously led the Middle East and Africa units in addition to Europe. Carlo De Notaristefani, 51, was named president for technical operations and global support functions, which gives him leadership on Bristol-Myers' information management. He had been president for technical operations, and had been in charge of the manufacturing business and global procurement. John Celentano, 49, will serve as president for the Asia Pacific region and for Emerging Markets, which includes Brazil, India, Russia and Turkey. He was previously in charge of the company's strategy and productivity initiatives. Giovanni Caforio, 44 will lead global and U.S. cancer operations. His prior role was head of the U.S. cancer unit.